EndoStim is a medical device company, based in St. Louis (Missouri) and Nijmegen (The Netherlands), focused on neurostimulation therapy for gastroesophageal reflux (GERD). The company has developed a unique, minimally-invasive implantable device designed to provide long-term reflux control by restoring normal esophageal function through low-energy personalized neurostimulation. The EndoStim system is already CE Marked for patients with GERD with symptom duration of six months or longer and is available in a number of countries throughout Europe, Latin America, and Asia Pacific.
We are very excited about EndoStim’s technology and the value it can bring to patients suffering from severe reflux disease. EndoStim’s minimally invasive neurostimulation therapy can offer a solution to patients not sufficiently treated with drug therapy while avoiding the side effects of more invasive surgical procedures.
EndoStim completed a USD 25 million Series D financing round from an investment syndicate consisting of Edeavour Vision, Gimv and Wellington Partners, alongside the company’s existing investors. This investment will fund the expansion of the company’s commercialization efforts and will enable it to conduct a pivotal U.S. clinical trial and the development of the next generation devices.